Thymulin is a
peptide hormone which is mainly produced by thymic epithelial cells and it has immune-modulatory and anti-inflammatory effects. In this study, we investigated the effects of different doses and various timings of
thymulin intraperitoneal administration on spinal microglial activity and intracellular pathways in an inflammatory rat model of Complete
Freund's adjuvant (CFA).
Thymulin treatment was implemented following CFA-induced
inflammation for 21 days. After conducting behavioral tests (
edema and
hyperalgesia), the cellular and molecular aspects were examined to detect the
thymulin effect on inflammatory factors and microglial activity. We demonstrated that
thymulin treatment notably reduced
thermal hyperalgesia and paw
edema induced by CFA. Furthermore, molecular investigations showed that
thymulin reduced CFA-induced activation of microglia cells, phosphorylation of
p38 MAPK and the production of spinal pro-inflammatory
cytokines (TNF-α, IL-6) during the study. Our results suggest that
thymulin treatment attenuates CFA-induced
inflammation. This effect may be mediated by inhibition of spinal microglia and production of central inflammatory mediators which seems to be associated with the ability of
thymulin to reduce
p38 MAPK phosphorylation. These data provide evidence of the anti-hyperalgesic effect of
thymulin on inflammatory
pain and characterize some of the underlying spinal mechanisms.